Beigene (NASDAQ:ONC) Price Target Raised to $313.00 at Macquarie

Beigene (NASDAQ:ONC) had its price target lifted by stock analysts at Macquarie from $259.00 to $313.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Macquarie’s target price indicates a potential upside of 16.10% from the company’s previous close.

Beigene Trading Down 3.2 %

Shares of NASDAQ ONC traded down $8.79 during trading on Friday, reaching $269.59. The company had a trading volume of 428,311 shares, compared to its average volume of 406,418. Beigene has a 52 week low of $126.97 and a 52 week high of $287.88. The company has a market cap of $26.38 billion, a PE ratio of -32.72, a P/E/G ratio of 7.73 and a beta of 0.63. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. As a group, equities analysts expect that Beigene will post -5.82 earnings per share for the current fiscal year.

Insider Transactions at Beigene

In other Beigene news, COO Xiaobin Wu sold 21,267 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $240.07, for a total value of $5,105,568.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $258.04, for a total transaction of $310,164.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,123 shares of company stock worth $14,081,527. 7.43% of the stock is owned by insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.